Article
Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.
The pharmacogenomics journal - 1 Jun 2014
Sebio A, Páez D, Salazar J, Berenguer-Llergo A, Paré-Brunet L, Lasa A, Del Río E, Tobeña M, Martín-Richard M, Baiget M, Barnadas A
Abstract excerpt
In the epidermal growth factor receptor (EGFR) pathway, polymorphisms in EGFR and its ligand EGF have been studied as biomarkers for anti-EGFR treatment. However, the potential pharmacogenetic role of other EGFR ligands such as amphiregulin (AREG) and epiregulin (EREG) has not been elucidated. We studied 74 KRAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
